Key Highlights
● Agenus (AGEN) closed at $9.43 on Monday, up 10.4% from $8.54, after Rodman & Renshaw began coverage at Buy.
● Analyst Michael King set a $19 price target, which is roughly 122% above Friday's closing price of $8.54.
● Intraday the stock reached $9.71, above its prior 52-week high of about $8.85, according to market data.
● No company announcement dated Monday was found, so the analyst initiation is the only identified new item for the stock.
Agenus (NASDAQ:AGEN) rose on Monday, September 28, closing at $9.43 against $8.54 on Friday, a gain of 10.4%. The move followed the start of coverage by Rodman & Renshaw, where analyst Michael King initiated with a Buy rating and a $19 price target. No Agenus press release dated Monday turned up in a check of company announcements.
What an Initiation Means
When a firm initiates coverage, it begins publishing regular research on a company for its clients. For smaller biotechs, that can widen the group of investors paying attention. A price target is the analyst's own estimate of where the stock could trade, usually over a year, and it is a view rather than a forecast. The $19 target sits roughly 122% above Friday's close.
According to market data, the stock reached $9.71 during the session, above its prior 52-week high of about $8.85, and the company's Market Value was about $386 million before the move. The same data listed four Buy ratings, one Hold and one Sell on the stock, with an average target of $24.50. Analyst views on the stock differ, and this initiation is one of several, so it does not settle the debate on the shares.
The Science Behind the Call
Agenus is an immuno-oncology company, meaning it develops drugs that help the immune system attack cancer. Its lead program combines botensilimab, which targets the CTLA-4 checkpoint, with balstilimab, which targets PD-1. Checkpoints act as brakes on immune cells, and blocking them can let the body attack tumours. The company has focused on cancers that have responded poorly to earlier immunotherapies, including microsatellite-stable colorectal cancer.
Biotech and the Broader Market
The three major benchmarks all ended in the red, with the S&P 500 off 59.72 points at 7,683.69, the Dow off 347.11 points at 51,481.51 and the Nasdaq Composite off 248.34 points at 26,820.38. Kodiak Sciences (NASDAQ:KOD) also drew attention to smaller drug developers with its trial results on the same day. Across the market, small caps lagged. The Russell 2000 fell 19.64 points, and lows swamped highs on the Nasdaq, 461 to 50. Yields were the story: the 10-year Treasury climbed to a level not seen since 2007, and the 30-year to one not seen since 2004, raising the hurdle for equities.
What to Watch for Agenus
The next test is whether interest from new coverage lasts beyond one session, since moves on analyst initiations can fade if no further news arrives. Updates on botensilimab and balstilimab, including any regulatory talks or new clinical data, will matter more over time, and they would appear in company press releases and SEC filings.
Views from other analysts and any change in funding plans are also worth following for a company of this size. Investors will parse a full slate of data this week: JOLTS and consumer confidence on Tuesday, PCE Inflation on Wednesday, ISM Manufacturing on Thursday and the September jobs report on Friday.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...